内容紹介
Summary
Patients with metastatic colon cancer can be treated with alternating courses of FOLFOX6 and FOLFIRI in order to reduce their adverse events. We report 2 patients with para-aortic lymph node metastasis treated with 4 courses each of FOLFOX6 and FOLFIRI in combination with bevacizumab, which led to a complete response. Case 1: The patient was a 53-year-old woman with transvers colon cancer tub2 pSS, ly3, v2, n4, H0, P0. Case 2: The patient was a 60-year-old woman with upper rectal cancer tub1 pSS, ly3, v3, n4, H0, P0. The administration of tegafur/uracil plus oral Leucovorin was continued for 6 months. Furthermore, only the administration of oral doxifluridine was continued for 4 years. Complete response has been maintained for over 5 years since resection. Four courses each of FOLFOX6 and FOLFIRI in combination with bevacizumab will not only provide a remission rate of 100% but will also be effective radical therapy for patients with para-aortic lymph node metastasis.
要旨
FOLFOXとFOLFIRIをそれぞれの有害事象を減らすため,4回ずつ交互に行う交代療法(FIREFOX)にbevacizumabを加えた化学療法を施行し,大動脈周囲リンパ節に転移を示した2例でcomplete response(CR)が得られ,かつ5年生存が得られた。症例は53歳,女性と60歳,女性。それぞれpSS,ly3,v2,n4,H0,P0の狭窄を伴う横行結腸癌と,pSS,ly3,v3,n4,H0,P0の上部直腸癌であった。2例とも手術施行後,4か月間8コースのFIREFOX+bevacizumabを施行し,その後tegafur/uracil+経口Leucovorin療法を6か月間施行し,さらにdoxifluridineを4年間内服した。2例とも5年を経過するも,再発なくCRの状態が続いている。FIREFOX+bevacizumabは切除不能大腸癌に対して奏効率100%を示すだけではなく,比較的小さなリンパ節転移症例に対しては5年生存が得られる可能性がある有効な化学療法と考えた。
目次
Patients with metastatic colon cancer can be treated with alternating courses of FOLFOX6 and FOLFIRI in order to reduce their adverse events. We report 2 patients with para-aortic lymph node metastasis treated with 4 courses each of FOLFOX6 and FOLFIRI in combination with bevacizumab, which led to a complete response. Case 1: The patient was a 53-year-old woman with transvers colon cancer tub2 pSS, ly3, v2, n4, H0, P0. Case 2: The patient was a 60-year-old woman with upper rectal cancer tub1 pSS, ly3, v3, n4, H0, P0. The administration of tegafur/uracil plus oral Leucovorin was continued for 6 months. Furthermore, only the administration of oral doxifluridine was continued for 4 years. Complete response has been maintained for over 5 years since resection. Four courses each of FOLFOX6 and FOLFIRI in combination with bevacizumab will not only provide a remission rate of 100% but will also be effective radical therapy for patients with para-aortic lymph node metastasis.
要旨
FOLFOXとFOLFIRIをそれぞれの有害事象を減らすため,4回ずつ交互に行う交代療法(FIREFOX)にbevacizumabを加えた化学療法を施行し,大動脈周囲リンパ節に転移を示した2例でcomplete response(CR)が得られ,かつ5年生存が得られた。症例は53歳,女性と60歳,女性。それぞれpSS,ly3,v2,n4,H0,P0の狭窄を伴う横行結腸癌と,pSS,ly3,v3,n4,H0,P0の上部直腸癌であった。2例とも手術施行後,4か月間8コースのFIREFOX+bevacizumabを施行し,その後tegafur/uracil+経口Leucovorin療法を6か月間施行し,さらにdoxifluridineを4年間内服した。2例とも5年を経過するも,再発なくCRの状態が続いている。FIREFOX+bevacizumabは切除不能大腸癌に対して奏効率100%を示すだけではなく,比較的小さなリンパ節転移症例に対しては5年生存が得られる可能性がある有効な化学療法と考えた。